SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549f
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June, 2019
Commission File Number 1-15182
DR. REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ¨ No x
If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY’S LABORATORIES LIMITED (Registrant) | |||
Date: June 14, 2019 | By: | /s/ Sandeep Poddar | |
Name: | Sandeep Poddar | ||
Title: | Company Secretary |
Exhibit 99.1
Dr. Reddy’s Laboratories Ltd. | |
8-2-337, Road No. 3, Banjara Hills, | |
Hyderabad - 500 034, Telangana, | |
India. | |
CIN: L85195TG1984PLC004507 | |
Tel :+91 40 4900 2900 | |
Fax :+91 40 4900 2999 | |
Email :mail@drreddys.com | |
www.drreddys.com |
June 14, 2019
Corporate Relationship Department | National Stock Exchange of India Ltd. | |||
BSE Limited | “Exchange Plaza” | |||
Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), | |||
Mumbai – 400 001 | Mumbai – 400 051 | |||
Fax Nos.: | 022-22723121 / 22723719 / | Fax Nos.: | 022-26598120/ 26598237/ | |
22722037 / 22722039 | 26598238 | |||
Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Dear Sirs,
Sub: Press Release
Please find enclosed a Press Release on “Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC”
This is for your information.
With regards,
Vikas Sabharwal | |
Assistant Company Secretary |
Encl: As above
CC:- New York Stock Exchange Inc.(Stock Code: RDY)
CONTACT | ||
DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. |
AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) |
MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40-4900 2121) |
Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC
Hyderabad, India, June 14, 2019 | For Immediate Release |
Hyderabad, India and Princeton, NJ, USA. June 14, 2019 - Dr. Reddy’s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announces that it has entered into a definitive asset purchase agreement with Upsher-Smith Laboratories, LLC (Upsher-Smith), pursuant to which Dr. Reddy’s would sell its US and select territory rights for ZEMBRACE® SYMTOUCH® (sumatriptan injection) 3 mg and TOSYMRATM (sumatriptan nasal spray) 10 mg, (formerly referred to as “DFN-02”), which are commercialized through its wholly owned subsidiary, Promius Pharma, LLC.
Under the agreement, Dr.Reddy’s will receive U.S.$70 million as upfront consideration, U.S.$40.5 million in near term milestones and additional financial considerations including, existing contractual obligation and inventory. Subsequently, Dr. Reddy’s will receive sales based royalties on a quarterly basis.
The closing of the transaction is subject to various customary closing conditions including antitrust review under Hart-Scott-Rodino Act.
“This is a testament to our strong R&D capabilities, and delivering solutions to unmet needs of patients. In a short time, we created a well-recognized migraine specialty business in the US and we look forward to our partnership with Upsher-Smith” said G.V. Prasad, Co-Chairman and CEO, Dr. Reddy’s Laboratories Limited.
“Tosymra and Zembrace were designed and developed with the goal of addressing unmet needs of large but discrete segments of patients suffering from episodic migraine who need options other than their current therapies. We are excited to partner with Upsher-Smith which has established a strong presence in neurology” said Anil Namboodiripad, Ph.D., Senior Vice President, Proprietary Products and Head, Promius Pharma.
Important Patient Safety Information for Zembrace SymTouch (sumatriptan injection) 3 mg and TOSYMRA (sumatriptan nasal spray) 10 mg.
Zembrace SymTouch and TOSYMRA can cause serious side effects, including: heart attack and other heart problems, which may lead to death.
Do not use Zembrace SymTouch and TOSYMRA if you have:
• | heart problems or a history of heart problems |
• | narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease) |
• | uncontrolled high blood pressure |
• | severe liver problems |
• | hemiplegic migraines or basilar migraines. If you are not sure if you have these, ask your healthcare provider |
• | had a stroke, transient ischemic attacks (TIAs), or problems with your blood circulation |
• | taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your healthcare provider if you are not sure if your medicine is listed above |
• | are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your healthcare provider or pharmacist for a list of these medicines if you are not sure. |
• | an allergy to sumatriptan or any of the ingredients in Zembrace SymTouch and TOSYMRA. |
You are encouraged to report negative side effects of prescription drugs. To report SUSPECTED SIDE EFFECTS, call Promius Pharma at 1-888-966-8766 or contact the FDA at 1-800-FDA-1088 (1-800-332-1088) or online at http://www.fda.gov/Safety/MedWatch
Please see Full Prescribing Information for Zembrace SymTouch and TOSYMRA.
For more information, please visit www.zembrace.com and www.mytosymra.com
COR-0619-356
About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr. Reddy’s operates in markets across the globe. Our major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com
About Promius Pharma LLC: Promius Pharma is a wholly-owned subsidiary of Dr. Reddy’s Laboratories, one of the largest and most respected pharmaceutical companies in the world. Promius Pharma is committed to bringing new products to market that meet patients’ needs. For more information, log on to: www.promiuspharma.com.
About Upsher Smith LLC: Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that strives to improve the health and lives of patients through an unwavering commitment to high-quality products and sustainable growth. Since 1919, it has brought generics and brands to a wide array of customers backed by an attentive level of service, strong industry relationships, and dedication to uninterrupted supply. For more information, visit www.upsher-smith.com.
Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.
The company assumes no obligation to update any information contained herein.
O$.R.5F8) GH7;9NV*95$$S]S+#V,=*^G;7&U_P!):G5%=>RGBC\W
M^ZU=A9W9W+^(+M+T(@-*3C5Y>V$&S3+-@!9^;32I&/HVBMYY))))-=RY.LZ7
M2+VTE.V7D;2F?K8G%$TGY_&I#5GN,7U>NP&OOCGAJGO(XITM5L2:L,Z+L&K&
MMGCJH2U:K-*)6Y>'BD5BM9"7%[%HILFXID27>O3 9$I#J$*'C;YYYQ3+MH6\
M:BI/X]NI49G3
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end
ZH(?7+ L_>'TDN;QMO<,Q>VLWN+6W$E
MLPQ:#0DB.9\E!HK1CB.T*D;F"P ^UNUQ [52XK;.N[%\3-,@TCXD=GTA?TL&[A!V@@Z:KHN6K
ME%-PV
MJ^/+Q3![1FO=EO1VI=BS28JJU?6IO[1YA2+8X[K
MY*HKZ<5-/%-8EC9&YT=S,PNVZAI<\+]$;\]:"X@*W[NU;<+;,W%1AW%:]8G6
M.PM9*$E191%39YJ76PFE;\?<:KOMX>U4:A;XTA"6TA_,Y1=&FM0]D=7#4&<@
MQ&9C[#S[LCU@Q8=C3L2F(9*3DVQH)4YBL(F"V$GU:5PEV!5)%V YGQMQUEV1M4
M^7 XN+W6]V,F]]I.HA@
MC<7S32+L:UX_\MA<@4A=IT0)4SR>9O,?R"/V>X4QT%VRV:^:Y1610DC>0?\
MU UQ<%/A2KPO[:_$-[-A9IW/76;]TG)T>9$MWKKE#([EW#JRSAN _&'&, KY
MD+&(E 41C:NG8(B]339
MB[P8EIPMPTR%A+MS@2?XA+D4^"H->@IU+RBPG)7REF,5V1!FNLNV4&R. _#E
MQF=Y#7J83K9>H8!U"42ZA\/%-TTSV]_G[&39:HYA:A:\%S=I[ $$ G3L-*<[
MK'8"Y FO'%OF\I:[:=R?\)!3KI6@JZ3(GJMFUPKDJ;/IY(./POW)71[Q#%#,
M31N:BQ);K(N J B^*"GM]^N\M_CHYG#,6NUW0[/)V[ !!IWZ=ZYOQE_&P/Q,
MRQ]@\EW[UJ]*CE5Y?+E9S11F@$'##-LB9?FT4F55%8WF3.>3_\ MAA6.1WG&P)20I0,
MMKL!+I*R^@R-X^_D8YF,MV;W-[NU 9'IH-[R ?@I[4CNC<-C$43"VZF?M:3U
M"!2[3KM;K\TI^,.Q^MQ;'*VBJ&%9AU[2LH;OSS)K^^\JSLI"[N3+2RD*3TE\
MU5QYXR(E55TV3W9OI3=.4%W;P\ / #H!V%22QMXH+1D6T@ ?4^)/B3U)\:VU
MK:PZ:$[86#H,1&!(G7C,0$-@,@'
2R-:Z5OIO;L
MD,;AM*H5!+3KH0:YG=G/UODCC3MGX4R"P&CX/Y@[LZ/,\KJ
H4\$WTCOKV^FB82$
MC:1TT"=3_3QKGAK;'QR3.8FY"FOX=*Y _=A*9(X,LN-K6P7&J#EKO+XJQ[+K
MI*Z/9V-9BE5AH9JEO61)<^LCOGZS%&3'J?!'&P,-T4M>BO82)DG*7L$L)V!0C
MGJ#L5VFH7Z5%LSRB&]$5GAV$W#907^4GR(0NG34C6G,X_26[C59+RRE;"=1@
M^-!/L&FALDI&MF($Z?ZC9ROG% Z/4J2@@DJHOOU&LH_\K(;>Q!]-[PK&%0IZ
M]-#J?"IMB&-GM&NN2DB%=W4?'6FQSO)YF?/0L/Q,BG5TF2\"(\)QUR.3'?#S
M"ES6B:?KL$J9BAZXQ!';,>F.RJ@X1H]8W$QX9OZI.3^=8I3NT%06H=-Y!ZZA
MG4ZA*:;_ "4WK_I5KYXW=7C7K\?A3W\>X'&PND6$;S]G;3YW6U8HVW]FBBC;;VZ**KLJ>U%T45
M3111HHHT458XT#WRF**JKX+MLJ+\55$W7PT45HSJ)@2UD1Y0@BH"*A(*KL.V
MZ?,B^W112AZR^/\ A^FBBJ>*^.RK_#1154ZD]B+_ "T457<_Q_E_Z:**MV7X
M+_)=%%&R_!?Y+HHHV7X+_)=%%&R_!?Y+HHHV5/:BZ**-E^"_RT453;?V:**-
FO=[]%%5V5/:BZ**IHHHVW]FBBJ^_\OX].^W]^VLJ/V5OV^E?_]D!
end